Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial (Q28202251)

0 references

P Romano

0 references

L D Mulcahy

0 references

L T Dooley

0 references

D G Baker

0 references

A B Gottlieb

0 references

language of work or name

English

0 references

publication date

9 June 2001

0 references

published in

The Lancet

0 references

volume

357

0 references

issue

9271

0 references

page(s)

1842-7

0 references

uses

randomized experiment

0 references

cites work

Treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904954-0

7 January 2021

The economic impact of psoriasis increases with psoriasis severity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904954-0

7 January 2021

Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904954-0

7 January 2021

The pathogenesis of psoriasis: immunological facts and speculations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904954-0

7 January 2021

Immunopathogenesis of psoriasis. The road from bench to bedside is a 2-way street

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904954-0

7 January 2021

The immunology of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904954-0

7 January 2021

Aetiology and pathogenesis of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904954-0

7 January 2021

Psoriasis. Immunopathology and immunomodulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904954-0

7 January 2021

Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904954-0

7 January 2021

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904954-0

7 January 2021

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904954-0

7 January 2021

Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904954-0

7 January 2021

Severe Psoriasis – Oral Therapy with a New Retinoid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904954-0

7 January 2021

Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904954-0

7 January 2021

Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904954-0

7 January 2021

Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904954-0

7 January 2021

IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904954-0

7 January 2021

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904954-0

7 January 2021

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904954-0

7 January 2021

Tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904954-0

7 January 2021

Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904954-0

7 January 2021

Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904954-0

7 January 2021

Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904954-0

7 January 2021

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904954-0

7 January 2021

10.1016/S0140-6736(00)04954-0

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

11410193

1 reference

Consolidated OpenCitations Corpus – April 2017